181 related articles for article (PubMed ID: 10776439)
1. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery.
Ercolani G; Grazi GL; Callivà R; Pierangeli F; Cescon M; Cavallari A; Mazziotti A
Surgery; 2000 Apr; 127(4):464-71. PubMed ID: 10776439
[TBL] [Abstract][Full Text] [Related]
2. Reassessment of monoethylglycinexylidide as preoperative liver function test in a rat model of liver cirrhosis and man.
Kaneko H; Otsuka Y; Katagiri M; Maeda T; Tsuchiya M; Tamura A; Ishii T; Takagi S; Shiba T
Clin Exp Med; 2001 Mar; 1(1):19-26. PubMed ID: 11467398
[TBL] [Abstract][Full Text] [Related]
3. Operative risk by the lidocaine test (MEGX) in resected patients for HCC on cirrhosis.
Ravaioli M; Grazi GL; Principe A; Ercolani G; Cescon M; Gardini A; Varotti G; Del Gaudio M; Cavallari A
Hepatogastroenterology; 2003; 50(53):1552-5. PubMed ID: 14571784
[TBL] [Abstract][Full Text] [Related]
4. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
Zotz RB; von Schönfeld J; Erhard J; Breuer N; Lange R; Beste M; Goebell H; Eigler FW
Transplantation; 1997 Feb; 63(4):538-41. PubMed ID: 9047147
[TBL] [Abstract][Full Text] [Related]
5. Lidocaine metabolite formation as a measure of perioperative liver function.
Shimanuki K; Sakurabayashi I; Miyata M; Kiyozaki H; Suzuki W; Kashii A; Seo N
Surg Today; 1993; 23(4):315-9. PubMed ID: 8318785
[TBL] [Abstract][Full Text] [Related]
6. Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.
Huang YS; Lee SD; Deng JF; Wu JC; Lu RH; Lin YF; Wang YJ; Lo KJ
J Hepatol; 1993 Aug; 19(1):140-7. PubMed ID: 8301034
[TBL] [Abstract][Full Text] [Related]
7. Monoethylglycinexylide formation in assessing pediatric donor liver function.
Rossi SJ; Schroeder TJ; Vine WH; A-Kader HH; Gremse DA; Ryckman FC; Pedersen SH; Pesce AJ; Balistreri WF
Ther Drug Monit; 1992 Dec; 14(6):452-6. PubMed ID: 1485364
[TBL] [Abstract][Full Text] [Related]
8. [Monoethylglycinexylidide--a metabolite of lidocaine--as an index of liver function in chronic hepatic parenchymal diseases].
Kupcová V; Turecký L; Szántová M; Schmidtová K
Bratisl Lek Listy; 1999 Jan; 100(1):12-24. PubMed ID: 10492993
[TBL] [Abstract][Full Text] [Related]
9. Monoethylglycinexylidide (MEGX) as a liver function test in cirrhosis.
Bhise SB; Dias RJ
Indian J Gastroenterol; 2007; 26(4):167-9. PubMed ID: 17986743
[TBL] [Abstract][Full Text] [Related]
10. Assessment of hepatic reserve for indication of hepatic resection: how I do it.
Lee WC; Chen MF
J Hepatobiliary Pancreat Surg; 2005; 12(1):23-6. PubMed ID: 15754095
[TBL] [Abstract][Full Text] [Related]
11. Safe use of liver donors with MEGX values less than 90 ng/mL.
Tesi RJ; Elkhammas EA; Davies EA; Salazar A; Henry ML; Greenson J; Ferguson RM
Transplant Proc; 1993 Feb; 25(1 Pt 2):1655-6. PubMed ID: 8442226
[No Abstract] [Full Text] [Related]
12. The unreliability of the lidocaine/monoethylglycinexylidide test for assessment of liver donors.
Reding R; Wallemacq P; de Ville de Goyet J; Lerut J; Hausleithner V; Feyaerts A; Lambotte L; Otte JB
Transplantation; 1993 Aug; 56(2):323-6. PubMed ID: 8356585
[TBL] [Abstract][Full Text] [Related]
13. The validity of the MEGX test in correlation with histology after orthotopic rat liver transplantation.
Keck H; Bachmann S; Knoop M; Dobis C; Meyer A; Neuhaus P
Transpl Int; 1994; 7 Suppl 1():S208-12. PubMed ID: 11271204
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the monoethylglycinexylidide (MEGX)-test prior to liver resection.
Lorf T; Schnitzbauer AA; Schaefers SK; Scherer MN; Schlitt HJ; Oellerich M; Becker H; Obed A
Hepatogastroenterology; 2008; 55(82-83):539-43. PubMed ID: 18613404
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the monoethylglycinexylidide liver function test in assessing donor liver suitability.
Fairchild R; Solomon H; Contis J; Kaminski D
Arch Surg; 1996 Oct; 131(10):1099-102. PubMed ID: 8857911
[TBL] [Abstract][Full Text] [Related]
16. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.
Oellerich M; Burdelski M; Lautz HU; Schulz M; Schmidt FW; Herrmann H
Ther Drug Monit; 1990 May; 12(3):219-26. PubMed ID: 2349604
[TBL] [Abstract][Full Text] [Related]
17. Monoethylglycinexylidide production as a measure in predicting hepatic histology.
Forte G; Rocco P; Costanzo A; Grimaldi E; Rossi R; Bottiglieri ME; Biceglia O; Zampella G
Ital J Gastroenterol; 1994 May; 26(4):159-62. PubMed ID: 7949258
[TBL] [Abstract][Full Text] [Related]
18. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease.
Shiffman ML; Luketic VA; Sanyal AJ; Thompson EB
Ther Drug Monit; 1996 Aug; 18(4):372-7. PubMed ID: 8857553
[TBL] [Abstract][Full Text] [Related]
19. [Multiple organ failure after severe trauma: predictable by the MEGX liver function test?].
Pape D; Lehmann U; Oellerich M; Regel G
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():338-9. PubMed ID: 9101869
[TBL] [Abstract][Full Text] [Related]
20. Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?
Testa R; Valente U; Risso D; Caglieris S; Giannini E; Fasoli A; Botta F; Dardano G; Lantieri PB; Celle G
Eur J Gastroenterol Hepatol; 1999 May; 11(5):559-63. PubMed ID: 10755262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
